Home › Non-Muscle Invasive Bladder Cancer › Kansas › Kansas City
Non-Muscle Invasive Bladder Cancer clinical trials in Kansas City, KS
4 studies for Non-Muscle Invasive Bladder Cancer are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
RecruitingPhase 2
- University of Kansas Medical Center (KUMC), Kansas City
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RecruitingPhase 1
- The University of Kansas Hospital Cambridge North Tower A, Kansas City
- The University of Kansas Hospital, Kansas City
- The University of Kansas Medical Center Medical Office Building, Kansas City
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
RecruitingPhase 1/2
- University of Kansas Medical Center, Kansas City
Blue Light Cystoscopy With Cysview® Registry
RecruitingObservational study
- University of Kansas Medical Center, Kansas City
Non-Muscle Invasive Bladder Cancer trials in other cities
- Columbus, OH10 studies
- Dallas, TX10 studies
- New York City, NY10 studies
- Myrtle Beach, SC9 studies
- Edison, NJ9 studies
- Baltimore, MD8 studies
- Syracuse, NY8 studies
- Nashville, TN8 studies
- Houston, TX7 studies
- Indianapolis, IN7 studies
- Philadelphia, PA7 studies
- Birmingham, AL7 studies
Other studies in Kansas City
- Cardiovascular Disease14 studies
- Heart Failure13 studies
- Obesity13 studies
- Interstitial Lung Diseases13 studies
- Cystic Fibrosis13 studies
- Breast Cancer12 studies
- Bladder Cancer12 studies
- Acute Myeloid Leukemia12 studies
- Prostate Cancer12 studies
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer11 studies
- COPD9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.